Amivantamab-lazertinib ups survival in EGFR-mutated advanced lung cancer
For patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), amivantamab-lazertinib yields improved progression-free survival compared with osimertinib as first-line treatment, according to a study published ...
Jul 1, 2024
0
0